| Characteristics . | Value . |
|---|---|
| Age, years (median, IQR) | 33.5 (27–50.5) |
| Female, sex, n (%) | 58 (69%) |
| Current smokers, n (%) | 3 (3.6%) |
| Comorbiditiesa, n (%) | 12 (14.3%) |
| Clinical Features | |
| Symptomatic at diagnosis, n (%) | 74 (88.1%) |
| Days from symptoms onset until 1st PCR (median, IQR) | 3 (1–6) |
| Days from symptoms onset until 2nd PCR (median, IQR) | 15 (14–19) |
| Symptoms, n (%) | 77 (91.7%) |
| Cough, n (%) | 56 (66.7%) |
| Fever, n (%) | 23 (27.4%) |
| Dyspnea, n (%) | 10 (11.9%) |
| Hyposmia/anosmia, n (%) | 35 (41.7%) |
| Dysgeusia, n (%) | 26 (31%) |
| Gastrointestinal disorders, n (%) | 17 (20.2%) |
| Asymptomatic, n (%) | 7 (8.3%) |
| Treatment, n (%) | 5 (6%) |
| Serology SARS-CoV-2 IgG | |
| Positive, n (%) | 80 (98.8%) |
| Negative, n (%) | 1 (1.2%) |
| Days from symptom onset until positive serology (median, IQR) | 44 (36–52) |
| Characteristics . | Value . |
|---|---|
| Age, years (median, IQR) | 33.5 (27–50.5) |
| Female, sex, n (%) | 58 (69%) |
| Current smokers, n (%) | 3 (3.6%) |
| Comorbiditiesa, n (%) | 12 (14.3%) |
| Clinical Features | |
| Symptomatic at diagnosis, n (%) | 74 (88.1%) |
| Days from symptoms onset until 1st PCR (median, IQR) | 3 (1–6) |
| Days from symptoms onset until 2nd PCR (median, IQR) | 15 (14–19) |
| Symptoms, n (%) | 77 (91.7%) |
| Cough, n (%) | 56 (66.7%) |
| Fever, n (%) | 23 (27.4%) |
| Dyspnea, n (%) | 10 (11.9%) |
| Hyposmia/anosmia, n (%) | 35 (41.7%) |
| Dysgeusia, n (%) | 26 (31%) |
| Gastrointestinal disorders, n (%) | 17 (20.2%) |
| Asymptomatic, n (%) | 7 (8.3%) |
| Treatment, n (%) | 5 (6%) |
| Serology SARS-CoV-2 IgG | |
| Positive, n (%) | 80 (98.8%) |
| Negative, n (%) | 1 (1.2%) |
| Days from symptom onset until positive serology (median, IQR) | 44 (36–52) |
Abbreviations: IgG, immunoglobulin G; IQR, interquartile range; n, number of patients; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
aComorbidities include dyslipidemia, hypertension, chronic lung disease, ischemic heart disease, chronic kidney disease, and neoplasm.
| Characteristics . | Value . |
|---|---|
| Age, years (median, IQR) | 33.5 (27–50.5) |
| Female, sex, n (%) | 58 (69%) |
| Current smokers, n (%) | 3 (3.6%) |
| Comorbiditiesa, n (%) | 12 (14.3%) |
| Clinical Features | |
| Symptomatic at diagnosis, n (%) | 74 (88.1%) |
| Days from symptoms onset until 1st PCR (median, IQR) | 3 (1–6) |
| Days from symptoms onset until 2nd PCR (median, IQR) | 15 (14–19) |
| Symptoms, n (%) | 77 (91.7%) |
| Cough, n (%) | 56 (66.7%) |
| Fever, n (%) | 23 (27.4%) |
| Dyspnea, n (%) | 10 (11.9%) |
| Hyposmia/anosmia, n (%) | 35 (41.7%) |
| Dysgeusia, n (%) | 26 (31%) |
| Gastrointestinal disorders, n (%) | 17 (20.2%) |
| Asymptomatic, n (%) | 7 (8.3%) |
| Treatment, n (%) | 5 (6%) |
| Serology SARS-CoV-2 IgG | |
| Positive, n (%) | 80 (98.8%) |
| Negative, n (%) | 1 (1.2%) |
| Days from symptom onset until positive serology (median, IQR) | 44 (36–52) |
| Characteristics . | Value . |
|---|---|
| Age, years (median, IQR) | 33.5 (27–50.5) |
| Female, sex, n (%) | 58 (69%) |
| Current smokers, n (%) | 3 (3.6%) |
| Comorbiditiesa, n (%) | 12 (14.3%) |
| Clinical Features | |
| Symptomatic at diagnosis, n (%) | 74 (88.1%) |
| Days from symptoms onset until 1st PCR (median, IQR) | 3 (1–6) |
| Days from symptoms onset until 2nd PCR (median, IQR) | 15 (14–19) |
| Symptoms, n (%) | 77 (91.7%) |
| Cough, n (%) | 56 (66.7%) |
| Fever, n (%) | 23 (27.4%) |
| Dyspnea, n (%) | 10 (11.9%) |
| Hyposmia/anosmia, n (%) | 35 (41.7%) |
| Dysgeusia, n (%) | 26 (31%) |
| Gastrointestinal disorders, n (%) | 17 (20.2%) |
| Asymptomatic, n (%) | 7 (8.3%) |
| Treatment, n (%) | 5 (6%) |
| Serology SARS-CoV-2 IgG | |
| Positive, n (%) | 80 (98.8%) |
| Negative, n (%) | 1 (1.2%) |
| Days from symptom onset until positive serology (median, IQR) | 44 (36–52) |
Abbreviations: IgG, immunoglobulin G; IQR, interquartile range; n, number of patients; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
aComorbidities include dyslipidemia, hypertension, chronic lung disease, ischemic heart disease, chronic kidney disease, and neoplasm.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
